Discussion Topic: Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE)
Please join host Jason T. Jacobson, MD, FHRS at HRS 2025 in San Diego as he discusses this article with Marmar Vaseghi, MD, MS, PhD, FHRS and Mayank Sardana, MBBS, MS. The prospective, multicenter, randomized BRAVE trial evaluated epicardial catheter ablation targeting the arrhythmogenic substrate in Brugada syndrome patients with implantable cardioverter-defibrillators (ICDs) to prevent ventricular fibrillation (VF). After a planned interim analysis of 52 patients, ablation significantly reduced VF episodes compared with controls (hazard ratio 0.29; P = .018), prompting early trial termination—approximately 83% remained VF-free after one procedure and 90% after a repeat, with a low complication rate (one hemopericardium).
Host: Jason T. Jacobson, MD, FHRS
Guests: Marmar Vaseghi, MD, MS, PhD, FHRS and Mayank Sardana, MBBS, MS
Speaker and Article Information: Download
Topic
- The Lead
Resource Type
- Podcasts
Related Resources

Podcasts
The Lead Episode 115: A Discussion of Socio-economic Position and Sudden Cardiac Death: A Danish Nationwide Study.
August 7, 2025

Podcasts
The Lead Episode 114: A Discussion of Lifestyle and risk factor modification in atrial fibrillation - A European Heart Rhythm Association survey LIVE from Heart Rhythm 2025 in San Diego
July 31, 2025

Podcasts
The Lead Episode 113: A Discussion on the Effect of Pulsed-Field Ablation on Human Coronary Arteries: A Longitudinal Study With Intracoronary Imaging LIVE from Heart Rhythm 2025 in San Diego
July 24, 2025